<DOC>
	<DOCNO>NCT01748240</DOCNO>
	<brief_summary>Azacytidine ( AZA ) current standard care frontline patient treat high-risk MDS clinically active type MDS , however , 50 % patient never respond . Vorinostat orally available HDAC inhibitor clinical activity MDS proven vitro synergy AZA . Patient treat upfront combination agent show response base phase I/II data . In present study , use combination two drug try create synergetic effect generate response patient experience treatment failure AZA . All eligible patient treat Azacitidine oral vorinostat 6 cycle 28 day . Study Design</brief_summary>
	<brief_title>Addition Vorinostat Azacitidine Higher Risk MDS Phase II add-on Study Patients With Azacitidine Failure</brief_title>
	<detailed_description>Patients meet eligibility criterion administer vorinostat orally 300mg two time daily 7 day outline table 1.1 . AZA administer SC 75 mg/m2/day x 7 consecutive day maximum tolerate dose dose reduction AZA need enter trial minimum dose 50mg/m2/d 7 consecutive day . Each cycle last 28 day AZA start day 1 cycle vorinostat start day 3 . Patients receive 6 cycle unless progression document . Patients complete remission ( CR ) , partial remission ( PR ) , hematological improvement ( HI ) , treat progression .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Myelodysplastic syndrome ( WHO FAB classify ) include : RA , RARS , RCMD , RCMDRS RAEB , RAEBt CMML WBC &lt; 13000/mm3 ) IPSS score 1.5 high ( IPSS intermediate2 high risk category ) begin azacitidine , Absence response ( CR , PR , marrow CR HI accord IWG 2006 ) minimum 6 cycle azacitidine single agent 75 mg/m²/d 7 day per cycle . Patients previous dose reduction AZA may eligible maximum tolerate dose equal 350mg/m2/cycle ( i.e . 50 mg/m²/d 7 day 75mg/m2/d 5 day ) . Age egal 18 year ECOG performance status ≤ 2 ( cf . appendix 2 ) ; Patient must adequate organ function indicate follow laboratory value Renal Serum creatinine calculate creatinine clearancea &lt; 2 mg/dl OR ≥ 60 mL/min patient creatinine level &gt; 1.5 X institutional ULN Hepatic Serum total bilirubin ≤ 2.5 X ULN OR direct bilirubin ≤ ULN patient total bilirubin level ≥ 2 mg/dL . AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time ULN Alkaline Phosphatase ≤ 5 X ULN If &gt; 2.5 X ULN , liver fraction ≤ 2.5 X ULN Creatinine clearance calculate per institutional standard . Patient known refractory platelet transfusion . Patient ineligible allogeneic hematopoietic stem cell transplantation time inclusion study Adherence study visit schedule ; Women childbearing potential must : Agree use effective contraception without interruption throughout study 3 month end treatment ; Men must : Agree conceive treatment use effective contraception treatment period ( include period dose reduction temporary suspension ) 3 month end treatment partner childbearing potential . Agree learn procedure preservation sperm . Patient prior treatment HDAC inhibitor ( e.g. , depsipeptide NSC630176 , MS 275 , LAQ824 , PXD101 , LBH589 , MGCD0103 , CRA024781 , etc ) . Patients receive compound HDAC inhibitorlike activity , valproic acid , antitumor therapy enroll study . Patients receive compounds indication , e.g . valproic acid epilepsy , may enroll 30day washout period . Severe infection uncontrolled severe condition . Last dose AZA give 3 month enter trial . Patient already enrol another therapeutic trial investigational drug HIV infection active hepatitis B C. Patient know allergy hypersensitivity component vorinostat azacitidine . Active cancer , cancer year prior trial entry basal cell carcinoma carcinoma situ cervix breast . Less 30 day since prior treatment growth factor ( EPO , GCSF ) noncytotoxic agent ( include lowdose oral chemotherapy ) ; event prior treatment cytotoxic demethylating agent , interval 3 month require ; Patient systemic steroid stabilize equivalent ≤ 10 mg/day prednisone 4 week prior start study drug . Patients clinical evidence CNS leukemia . Patient history GI surgery procedure might interfere absorption swallow study drug . Women could become pregnant , currently breastfeed Patient eligible allotransplantation time inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>